Vectors for molecule delivery to CD11b expressing cells

摘要

The invention relates to a novel use of a Bordetella adenylcyclase toxin in the manufacturing of vectors for targeting in vivo a molecule of interest, specifically to CD11b expressing cells. The invention also relates to an immunogenic composition that primes immune responses, to pharmaceutical compositions and to a new vector for molecule delivery to CD11b expressing cells.

主权项

1. A proteinaceous vector comprising:
a) a Bordetella species adenylcyclase (CyaA) or a fragment thereof lacking all or part of residues 1-373, the CyaA or fragment thereof comprising an added cysteine residue genetically inserted into a permissive site in the catalytic domain of the CyaA or fragment thereof, or genetically placed at the N-terminal end of the CvaA or fragment thereof; and b) a peptide antigen comprising a T-cell epitope chemically coupled via a cysteine amino acid residue to the added cysteine residue in the CyaA or fragment thereof to thereby form a disulfide bond between the peptide antigen and the CyaA or fragment thereof, wherein the proteinaceous vector has the ability to bind to CD11b expressing dendritic cells such that the peptide antigen is translocated to the cytosolic pathway for MHC class I presentation; and wherein administration of the proteinaceous vector to a subject induces a cytotoxic T lymphocyte (CTL) response against the peptide antigen.